Sixteen years of qualification
Audited Supplier
In This Store
![LAMIVUDINE SALICYLATE; (2R-CIS)-4-AMINO-1[2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5- YL]-2(1H)-PYRIMIDINONE](https://eimg.pharmasources.com/image/20250312/IPeZ2XOAbUx8zehVFujfdCZ05f7kLW8xr300nzYx.jpg!200)
LAMIVUDINE SALICYLATE; (2R-CIS)-4-AMINO-1[2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5- YL]-2(1H)-PYRIMIDINONE
CME; (1R,2S,5R)-5-METHYL-2-(1-METHYLETHYL)CYCLOHEXYL (2R,5S)-5- (4-AMINO-2-OXO-1(2H)-PYRIMIDINYL)-1,
NCT; Carbonic acid 4-nitrophenyl 5-thiazolylmethyl ester; (5-Thiazolyl)methyl-(4-nitrophenyl)carbona
TENOFOVIR DISOPROXIL FUMARATE; 9-((R)-2-((BIS(((ISOPROPOXY CARBONYL)OXY)METHOXY)PHOSPHINYL)METHOXY)P
LOPINAVIR; (2S)-N-[(2R,4S,5S)-5-[[2-(2,6-DIMETHYLPHENOXY) ACETYL]AMINO]-4-HYDROXY-1,6-DIPHENYL-HEXAN
Molnupiravir; ((2R,3S,4R,5R)-3,4-dihydroxy-5-((Z)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-
![Dolutegravir sodium; (4R,12aS)-N-[(2,4-Difluorophenyl) methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-](https://eimg.pharmasources.com/image/20250312/IKsR24pPkSTr0GsZu1IlvmcZmveuOYsvxe9bngAn.jpg!200)
Dolutegravir sodium; (4R,12aS)-N-[(2,4-Difluorophenyl) methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-
Anhui Biochem Pharmaceutical Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and sales of chemical drugs in the field of antiviral medications for the treatment of diseases such as AIDS and hepatitis B.
The company currently holds 23 drug registration certificates for chemical formulations for the treatment of AIDS, hepatitis B, and other diseases, and has over 20 formulations under research awaiting registration approval.
Adhering to the integrated development concept of “active pharmaceutical ingredients (API) + formulations,” the company possesses the capability for the production and R&D of both APIs and formulations, and has mastered the core technologies of the entire industry chain from APIs to formulations. Some of the company's APIs and formulations have passed the WHO-PQ prequalification, and some API production management has passed the FDA on-site inspection, laying the foundation for the export of the company's products.
The company is committed to the integrated development of APIs and formulations. Its future business development will focus on antiviral drugs, continuously improving the range of generic drugs in the AIDS field, expanding generic drugs for other indications in the antiviral field, and closely following technological trends to conduct innovative drug research and development in areas such as AIDS and hepatitis B. As the company's product line continues to improve, it will accelerate the international registration and market promotion of its drugs, expand product exports, and achieve international development. The company will always take serving the treatment of major national diseases and scientific and technological innovation as its mission, and strive to become an international leading pharmaceutical enterprise in the field of AIDS treatment and other infectious diseases.
Year of Establishment: 2002
Total Assets(USD):
Total Number of Staff: 500-1000
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Other Competitive Advantages:
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight January 2025
![N-[[N-METHYL-N-[(2-ISOPROPYL-4-THIAZOLYL)METHYL]AMINO] CARBONYL]-L-VALINE; MTV III](https://eimg.pharmasources.com/image/20250312/JpBuftf8InMtroBn0d2UcBX3Cj4j9ti5ZanttSQG.jpg!200)
